Form 4: TherapeuticsMD CEO Marlan D. Walker Reports Stock Transactions
SEC Form 4
Marlan D. Walker, CEO of TherapeuticsMD, Inc., reports the acquisition of common stock through the settlement of performance stock units (PSUs) and restricted stock units (RSUs) on February 18, 2025.
Summary
- On February 20, 2025, Marlan D. Walker, the CEO of TherapeuticsMD, Inc., filed a Form 4 with the SEC.
- The report details transactions involving common stock acquired through the settlement of performance stock units (PSUs) and restricted stock units (RSUs) on February 18, 2025.
- Walker acquired a total of 8,281 shares of common stock through these settlements.
- The transactions did not involve any monetary exchange, as the price per share for the acquired stock was $0.
- Following these transactions, Walker directly owns 70,846 shares of TherapeuticsMD, Inc.
- The RSUs vested at various dates including July 1, 2024, September 29, 2024 and March 23, 2024.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment, but rather reflects pre-arranged compensation plans.
Positives
- The CEO's acquisition of shares, even through vesting of previously granted equity, could be interpreted as a positive sign of confidence in the company.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions have a minor dilutive effect on existing shareholders due to the issuance of new shares.
Key Dates
| Date | Description |
|---|---|
| March 23, 2023 | Start date for vesting of 1,733 RSUs in three equal annual installments. |
| March 23, 2024 | Date that 1,733 RSUs vested. |
| July 1, 2024 | Date that 2,311 RSUs vested. |
| September 29, 2024 | Date that 770 RSUs vested. |
| February 18, 2025 | Date of transaction where PSUs and RSUs were settled for common stock. |
| March 23, 2025 | Date that 1,733 RSUs will be fully vested. |
| February 20, 2025 | Date of Form 4 filing. |
Keywords
Form 4, TherapeuticsMD, TXMD, Marlan D. Walker, CEO, Stock Acquisition, Performance Stock Units, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.